Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab extended-interval dosing versus standard-interval dosing in relapsing-remitting multiple sclerosis
2018-002145-11Phase 3Unknown
- Sponsor
- Biogen
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Status: unknown.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2018-002145-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002145-11.